We need your help now
Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
Sign in. It’s quick, free and it’s up to you.
An account is an optional way to support the work we do. Find out more.
By continuing, you are indicating that you accept our Terms of Service and Privacy Policy.
TAOISEACH LEO VARADKAR has said it would be “inappropriate and unethical” if the company providing a life-saving drug to patients with a chronic lung condition was to cut off its supply to some Irish patients.
21 Alpha-1 patients in Ireland have been receiving the Respreeza drug up until now through a compassionate use programme.
However, the HSE failed to reach a price agreement with its manufacturer, CSL Behring, and it has decided not to fund the roll-out of Respreeza to all Irish patients.
In a statement in August, the HSE said that it did not find the clinical benefit of Respreeza to be “sufficiently strong in the context of the proposed cost and budget impact”.
It remains unclear if the manufacturer will cut-off the Respreeza supply to those under the compassionate use programme, as the HSE has received no formal notification of the intention to discontinue access to the compassionate scheme, according to Taoiseach Leo Varadkar.
Patients with the condition, also known as genetic emphysema, have a deficiency of the Alpha-1 antitrypsin protein, which can lead to severe lung, liver and skin problems. Most people with the condition develop emphysema or chronic obstructive pulmonary disease (COPD) at some stage in their lives.
The Alpha One Foundation said the drug “slows the progression of lung disease associated with Alpha-1″ and can lead to “fewer chest infections and less time spent in hospital”.
Speaking in the Dáil today, Varadkar condemned the possibility of the removal of the drug from those on the compassionate use programme:
It is completely inappropriate and unethical for any company to link reimbursement decisions to a compassionate access scheme and I would consider it unscrupulous if the company was not to honour any commitments which it has made to patients.
He said that the Minister for Health Simon Harris has directed the HSE to “seek assurances from the relevant hospital, Beaumont Hospital, that appropriate care arrangements are in place in the event of the access programme being discontinued by the company”.
[image alt="original" src="http://cdn.thejournal.ie/media/2017/09/original-227-266x400.jpg" width="266" height="400" credit-source="Sam%20Boal" credit-via="Rolling%20News" caption="Patient%20Josephine%20Mc%20Guirk%20with%20the%20Alpha-1%20Patient%20Action%20Group%0A" class="alignnone" /end]
‘Insufficient evidence of benefits’
Despite Varadkar’s strong words in relation to those under the compassionate scheme, he backed the HSE’s decision not to reimburse the drug.
“The HSE has carefully considered the pricing and reimbursement of the medicine through its decision-making process and there is insufficient evidence to suggest patients would drive a clinically meaningful benefit from this treatment,” he said.
He said that at the heart of the assessment process is “the rationale that decisions about the reimbursement of medicines in Ireland are made on an objective and scientific basis, taking into account expert opinion, as appropriate, and recognising the health needs of the population and other factors”.
Speaking in August when the decision was made not to reimburse the drug, Professor Michael Barry, Head of the National Centre for Pharmacoeconomics said:
“We know this is a difficult time for patients who have been affected by this decision. However, the cost-effectiveness of this drug has not been demonstrated following submissions from the manufacturer.
“The HSE has to consider the wider population and needs to manage the full range of health services to all of the other patient groups within the finite resources at its disposal.”
Calls for action
The efficacy of Alpha-1 has been recognised by the European Medicines Agency and it has already been approved in 12 European countries. It’s estimated that the drug could benefit up to 60 patients in Ireland.
The Alpha-1 Action Group and the Alpha One Foundation took part in two hour-long vigils in August – the first at the head office of the HSE, and the second at the Department of Health’s Hawkin’s Health offices.
[image alt="alpha 1" src="http://cdn.thejournal.ie/media/2017/09/alpha-1-4-296x245.jpg" width="296" height="245" credit-source="Sam%20Boal" credit-via="Rolling%20News" caption="Alpha-1%20Patient%20Action%20Group%20Protest" class="alignnone" /end]
They called on the HSE and Minister for Health Simon Harris to “put patients first and to hammer out a deal with the pharmaceutical company on making Respreeza available in Ireland”.
“Alpha-1 patients are becoming increasingly concerned and upset as they await a positive decision,” Geraldine Kelly, CEO of the Alpha One Foundation said.
‘We wouldn’t be here without it’
Johnny Hannan (67), from Mallow in Cork, is one of the patients who took part in the clinical trial.
“Respreeza has been clearly deemed to be of benefit for patients, so while policy-makers here might query its effectiveness, you have to wonder if they just think that we patients are not worth the investment,” Hannan said.
“For those of us lucky enough to have had access, we know we wouldn’t still be here without it. Respreeza has the potential to add years back onto people’s lives. For us, it really is a lifeline.”
About 350 people in Ireland have been diagnosed with the most severe form of Alpha-1. It’s thought about 3,000 people have this form of the condition but are yet to be diagnosed, while thousands more have a moderate deficiency.
To embed this post, copy the code below on your site
Have you noticed how Leo is always reported as saying something, but never actually as doing anything. He really does need to stop talking and get on with the walking. Time for action Leo, the socks and fancy friends playtime is over.
@Paul Fahey: Nail on the head there Paul.
No money left in the kitty as it’s all spent on traveling to egypt. Need money to pay for the private jet to fly to egypt
You know the people running your health service are petty, soulless pencil pushers when a For-Profit Corporation cares more about it’s patients than they do. Disgrace doesn’t go nearly far enough.
@John Considine: Try reading the article again.
@-: Trying reading the article again yourself, it states right in the article that the HSE had made this decision and Leo is backing them.
“The HSE has carefully considered the pricing and reimbursement of the medicine through its decision-making process and there is insufficient evidence to suggest patients would drive a clinically meaningful benefit from this treatment,”
@B9xiRspG: Yes; the HSE makes decisions with finite resources with the good of ALL patients in mind. In this case, like others it has decided against. This decision isn’t made by “pen pushers” but experienced physicians.
Secondly the company won’t agree a reduced fee with the HSE and won’t supply Ireland; something condemned by the pen pushers. Additionally the status of those already on it as unknown. Hardly the company caring more for the patients now is it?!
@John Considine: Sadly this is what my husband died from.
@-: how come drug prices in Ireland are far higher than in Europe?
How is it unethical for a company to stop supplying a drug which Leo/HSE stated as not being worth funding. You can’t have it both ways Leo.
@Murr Paul: regardless of how Leo / HSE try to spin it… legislation is very clear… Statutory Instruments. No. 374/2006 – European Communities (Clinical Trials on Medicinal Products for Human Use) (Amendment No. 2) Regulations 2006.
CONDITIONS AND PRINCIPLES THAT APPLY TO ALL CLINICAL TRIALS
1. Clinical trials shall be conducted in accordance with the ethical principles set out in the Declaration of Helsinki and the requirements of these Regulations.
Post-Trial Provisions for participants is clearly spelt out..
34. In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This information must also be disclosed to participants during the informed consent process.
@Murr Paul: regardless of how Leo or HSE try to spin it, legislation is very clear… Statutory Instruments. No. 374/2006 – European Communities (Clinical Trials on Medicinal Products for Human Use) (Amendment No. 2) Regulations 2006.
CONDITIONS AND PRINCIPLES THAT APPLY TO ALL CLINICAL TRIALS
1. Clinical trials shall be conducted in accordance with the ethical principles set out in the Declaration of Helsinki and the requirements of these Regulations.
Post-Trial Provisions for participants is clearly spelt out..
34. In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This information must also be disclosed to participants during the informed consent process.
I would imagine it will fo like it did a few months ago and agreement will be reached.
I had been hospitalized for 4 years in a row all in the same month march, for shortness of breath. They thought it was asthma. The last time which was this year, they hospitalized me for a week. Which they ran lots of test and determined I have COPD. The symptoms I had were shortness of breath, tired, and coughing.There has been little if any progress in finding a cure or reliable treatment. April this year my brother In law who’s an M.D suggested I started on Natural Herbal Gardens COPD Herbal formula which eased my anxiety a bit,We ordered their COPD herbal treatment after reading alot of positive reviews, i started on natural alternative COPD DISEASE treatment from ( www. naturalherbalgardens .com ) the treatment worked very effectively, i am happy to report with the help of Natural Herbal Garden natural herbs my severe symptoms simply vanished, i feel better now, this alternative COPD disease treatment is a breakthrough.Visit Natural Herbal Gardens official website This Herbal Protocol is Incredible!!
I would love you to contact totalcureherbalfoundation@gmail.com they shall provide you all the herbal formula that can help you get rid of COPD emphysema,for the past 9 years has been a terrible years for me because i was diagnosed with copd emphysema,i’m 59 and and fully cure of copd by Total cure herbal foundation which i found on-line,my condition was very bad which i have been currently on 24/7 oxygen, nebulizer, pro air.,early this year during my research on Google i found this herbal foundation which someone posted on how they help her with emphysema disease so i decided to email them also and they gave me all the steps which i did properly,the herbal medicine aims to return the body to a state of natural balance, so that it can start healing itself,email them now to stop your nightmare.
totalcureherbalfoundation@gmail.com
I am 59 now. I was diagnosed with COPD in March of 2013. I had been a heavy smoker, got a cold I couldn’t get rid of, ended up in the hospital, on a ventilator. I should have known it was coming, but like most smokers, thought it would never happen to me. I don’t smoke now and never will again, but, I still want to. My life has changed drastically. I had to stop working, sold my home (couldn’t afford it without a salary),the COPD disease has kept down since diagnosed if not for the herbal formula of Total cure herbal foundation i would have been in hospital with the use oxygen managing my condition,total cure herbal foundation finally get rid of my disease with their natural herbal products in just 14 weeks of usage which i have been on other medication for ages but am really glad now that my lungs has return to it normal position.
contact: https://totalcureherbalfou5.wixsite.com/herbal/contact
Totalcureherbalfoundation@gmail.com
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
Non-TCF/GVL Vendors
have your say